Paclitaxel-Related Macular Edema During Treatment for Metastatic Breast Cancer

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: ER-positive, HER2-negative

Cancer treatment continued with eribulin after paclitaxel was stopped because of vision toxicity in early 2021.

PubMed CentralRead more →

Stage III Breast Cancer Complicated by a Large Liver Abscess

Patient Info: Anonymized, Female, 70+ | Stage III

Biomarkers: ER-positive, HER2-negative

Continuing adjuvant anastrozole and oncology follow-up after mastectomy for Stage III breast cancer.

PubMed CentralRead more →

HER2-Positive Breast Cancer With Metastatic Progression and Drug-Induced Lupus During T-DM1

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: ER-positive, PR-negative, HER2-positive

Metastatic Site: bones, axillary lymph nodes, intra-abdominal lymph…

More than 5 years after her March 2018 diagnosis, she was living with metastatic breast cancer, but T-DM1 had been stopped after disease progression in 2023.

PubMed CentralRead more →

Stage IV luminal A breast cancer: liver resection and disease-free follow-up

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: luminal A; ER-positive; PgR-positive; HER2-negative

Metastatic Site: lung, liver

Disease-free after R0 hepatic segmentectomy for breast cancer liver metastasis, with May 2021 MRI showing no remaining liver nodules while she continued maintenance letrozole and goserelin.

PubMed CentralRead more →

Stage 4 HR-positive breast cancer: stable disease on ribociclib

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative

Metastatic Site: left iliac bone

Metastatic HR-positive, HER2-negative breast cancer remained without progression as of October 2024 while she continued ribociclib 400 mg plus letrozole after SBRT to a left iliac bone metastasis.

PubMed CentralRead more →

Stage I HR-Positive Invasive Lobular Carcinoma: Janelle's Patient Story

Patient Info: Janelle, Female, 40s | Stage I

Biomarkers: ER-positive; PR-positive; HER2-negative

As of December 2024, Janelle was living with a recent Stage IA ER-positive, PR-positive, HER2-negative lobular carcinoma diagnosis and using her research background to advocate for more inclusive ILC information and studies.

Lobular Breast Cancer AllianceRead more →

Stage IV luminal B breast cancer with liver, bone, and bone marrow metastases

Patient Info: Anonymized, Female, Under 40 | Stage IV

Biomarkers: ER 90% positive; PR 20% positive; HER2-negative; Ki-67 60%; luminal B

Metastatic Site: liver, bone, bone marrow

The patient had marked clinical and hematologic improvement on leuprorelin, letrozole, ribociclib, and zoledronic acid, with sustained complete remission reported for 4 months from September to December 2023 and monthly follow-up advised.

PubMed CentralRead more →

Breast Cancer and a Separate Intrahepatic Cholangiocarcinoma in a 35-Year-Old Woman

Patient Info: Anonymized, Female, Under 40

Biomarkers: ER-positive, PR-positive, HER2/CerbB-2 positive

Breast-cancer care continued with postoperative endocrine maintenance while a separate primary intrahepatic cholangiocarcinoma required additional treatment.

PubMed CentralRead more →

Metastatic Male Breast Cancer Responding to Abemaciclib and Letrozole

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: ER-positive, PR-negative, HER2-negative

Metastatic Site: soft tissue, distant lymph nodes, bone

The tumor and metastatic soft-tissue and lymph-node disease shrank markedly, with no progression on July 2024 imaging and good clinical condition in September 2024.

PubMed CentralRead more →

A Separate Early-Stage Breast Cancer Found During Treatment for Metastatic Adenoid Cystic Carcinoma

Patient Info: Anonymized, Female, 50s

Biomarkers: ER-positive, PR-positive, HER2-negative

The separate early-stage hormone-receptor-positive breast cancer remained untreated while care shifted to best supportive care for progressive metastatic adenoid cystic carcinoma.

PubMed CentralRead more →

Hormone receptor-positive breast cancer metastatic to the pituitary: surgery and disease-free follow-up

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: ER 2+; PR 1+; HER2 0; GATA3 positive; CA125 elevated

Metastatic Site: pituitary

Disease-free 11 months after surgical resection of pituitary metastasis from prior hormone receptor-positive, HER2-negative breast cancer, with postoperative recovery supported by antibiotics, hormone replacement/supportive therapy, and electrolyte management.

PubMed CentralRead more →

Severe Corneal Injury After Trastuzumab for Metastatic HER2-Positive Breast Cancer

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: ER-positive, PR-positive, HER2-positive

Metastatic Site: lungs, spine, left adrenal gland, calvarium, orbit,…

She was living with widespread metastatic breast cancer when trastuzumab was stopped because of severe eye toxicity.

PubMed CentralRead more →

HR-Positive Breast Cancer: Anna's Survivor Story

Patient Info: Anna, Female, Under 40

Biomarkers: ER-positive; PR-positive; HER2-positive

As of October 2024, Anna was about 7 years from diagnosis and described long-term survivorship after surgery, chemotherapy, radiation, biologic treatment, and tamoxifen-related mental-health effects.

The Patient StoryRead more →

Anna’s Triple-Positive Breast Cancer Story

Patient Info: Anna, Female, Under 40

Biomarkers: ER-positive, PR-positive and HER2-positive

Anna completed surgery, chemotherapy and radiation and continued to navigate the effects of hormone therapy, early menopause and fertility loss.

The Patient StoryRead more →

Stage IV HR-Positive Invasive Ductal Carcinoma: Dee's Patient Story

Patient Info: Dee, Female, Under 40 | Stage IV

Biomarkers: ER-positive

Metastatic Site: Bones

As of October 2024, Dee was living with Stage IV metastatic ER-positive breast cancer after bone metastases were found in 2023 and had adapted to treatment with ribociclib.

The Patient StoryRead more →

Stage II HER2-Positive Breast Cancer With Fever and a Reversible Brain MRI Lesion After Radiotherapy

Patient Info: Anonymized, Female, Under 40 | Stage II

Biomarkers: ER-positive, PR-positive, HER2-positive

After radiotherapy, fever, neutropenia, headache, and a reversible splenial brain lesion resolved with supportive and antibiotic treatment during her postoperative breast-cancer treatment course.

PubMed CentralRead more →

Hormone receptor-positive invasive lobular carcinoma treated with neoadjuvant chemotherapy

Patient Info: Anonymized, Female, 50s | Stage II

Biomarkers: ER-positive; PR-positive; HER2-negative; Ki-67 20%

Three-month follow-up showed the biopsy-related pseudoaneurysm had thrombosed and regressed, clearing the way for planned neoadjuvant chemotherapy and surgery; cancer response after planned treatment was not yet available.

PubMed CentralRead more →

Stage 1 invasive ductal breast cancer: nipple-preserving mastectomy with reconstruction

Patient Info: Anonymized, Female, 60s | Stage I

Biomarkers: ER-positive; PR-positive; HER2-negative; Ki-67 28%

No signs of recurrence 20 months after nipple-preserving mastectomy, sentinel node biopsy, immediate reconstruction, adjuvant chemotherapy, and endocrine therapy for ER-positive, PR-positive, HER2-negative invasive ductal breast cancer.

PubMed CentralRead more →

Stage 4 breast cancer: ongoing treatment with multi-line chemotherapy

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Initial tumor: hormone receptor-negative; HER2 2+. 2011 recurrence: ER 10%; PR 70%; HER2 2+.

Metastatic Site: pleura/pleural effusion; lung

Metastatic breast cancer with malignant pleural effusion achieved complete response after chemotherapy and long-term endocrine therapy; PET-CT in October 2023 still showed complete response, with ongoing cardiac and bone-health management.

PubMed CentralRead more →

ER-positive breast cancer: mastectomy after hormone therapy

Patient Info: Anonymized, Female, 50s | Stage II

Biomarkers: Breast cancer was ER+ and HER2-low/negative. PR changed from positive on biopsy to negative on final pathology; HNA-1 antibody found for neutropenia.

Stage IIA ER-positive invasive ductal breast cancer had no recurrence 3 years after endocrine therapy and total mastectomy with sentinel lymph node biopsy; autoimmune neutropenia was monitored rather than directly treated.

PubMed CentralRead more →

Right-Sided Ductal Carcinoma in Situ Before a Second Breast Cancer

Patient Info: Anonymized, female, 60s

Biomarkers: ER-positive; PR-positive; HER2 1+

A woman treated for right-sided ductal carcinoma in situ in 2018 later developed a separate invasive cancer in the opposite breast.

PubMed CentralRead more →

Stage 3 infiltrating ductal carcinoma treated with radical mastectomy

Patient Info: Anonymized, Male, 50s | Stage III

Biomarkers: Breast cancer was ER/PR positive, HER2 negative

The patient recovered fully after right radical mastectomy and complete axillary dissection for Stage III male breast infiltrating ductal carcinoma; adjuvant therapy and recurrence follow-up were not reported in the extracted case text.

PubMed CentralRead more →

Triple-positive breast cancer: complete response to targeted therapy

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Triple-positive breast cancer; SBDS variants present; no detected TP53 variant on MyeloSeq.

Metastatic Site: liver

Stage IV triple-positive breast cancer with liver metastasis achieved complete response after paclitaxel, trastuzumab, pertuzumab, and G-CSF support; complete response was maintained for 18 months after treatment initiation while on maintenance HER2-directed and endocrine therapy.

PubMed CentralRead more →

Stage 4 luminal A breast cancer: tumor regression on hormone therapy

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative

Metastatic Site: skin, soft tissue, lungs

Metastatic Luminal A breast cancer involving skin/soft tissue and lungs showed regressing tumors and stable lung metastasis after 3 months of anti-hormone therapy plus capecitabine; longer-term control was not reported.

PubMed CentralRead more →